Method of modulating the proliferation of medullary thyroid carcinoma cells

• US 20070259811A1
• Filed: 05/02/2007
• Published: 11/08/2007
• Est. Priority Date: 03/06/2001
• Status: Active Grant

• Current Assignee: Administrators Of The Tulane Educational Fund (ADMINISTRATORS|DAVID H. COY), Ipsen Pharma Sas (Ipsen Sa), The University of Ferrara
• Original Assignee: Ipsen Pharma Sas (Ipsen Sa)
• Inventors: Coy, David, Zatelli, Maria, Degli Uberti, Ettore, Culler, Michael
• Granted Patent: US 9,220,760 B2
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/31 Somatostatins
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Abstract

The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A somatostatin receptor antagonist having the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH₂ is also disclosed.

Claims

1. A method of modulating the rate of proliferation of medullary thyroid carcinoma cells (MTC) which comprises contacting MTC cells with one or more SSTR2 agonist and one or more somatostatin receptor subtype 5 (SSTR5) agonist, wherein said somatostatin receptor subtype 2 (SSTR2) agonist reduces the rate of proliferation of the MTC cells and said SSTR5 agonist attenuates the SSTR-2 agonist-induced reduction in cellular proliferation rate.

2. A method according to claim 1, wherein said SSTR-5 agonist is D-Phe-Phe-Trp-D-Trp-Lys-Thr-Phe-Thr-NH₂ (SEQ ID NO:

1) or a pharmaceutically acceptable salt thereof.

3. A somatostatin receptor antagonist comprising the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NH₂ (SEQ ID NO:

6) or a pharmaceutically acceptable salt thereof.